Epidemiologic investigations of women with female sexual dysfunction (FSD) from well-designed, random-sample, community-based populations are limited. Based on available information, FSD is common and estimated to occur in 22 ± 43% of women. There are limited data on age-related and para-aging risk factors, which are critical to understand when planning treatment and prevention efforts. Based on correlates of FSD, associated risk factors include age, education, history of sexual abuse or sexually transmitted disease, overall state general happiness and physical health. This brief overview attempts to review what is known about the female sexual anatomy, describes factors that may affect female sexual responsiveness, and identi®es several areas where additional research is needed to promote understanding of this complex physiological and psychosocial phenomenon.
Introduction
The female sexual response has been characterized as consisting of desire, arousal and orgasm phases. 1 ± 3 Desire involves the existence of sexual fantasies, thoughts, andaor receptivity to sexual activity. Desire is the mental state created by external and internal stimuli that induces a need or want to partake in sexual activity. Desire may be said to consist of: (1) biologic roots, which are in part based on hormones such as androgen and estrogen; (2) motivational roots, which are in part based on intimacy, pleasure and relationship issues; and (3) cognitive issues such as risk and wish. Arousal involves the ability to attain, or maintain adequate sexual excitement and may be experienced as subjective excitement or genital lubrication and or swelling or other somatic responses. Arousal is the state with speci®c feelings and physiologic changes usually associated with sexual activity involving the genitals. Arousal may be said to consist of: (1) central mechanisms including activation of thoughts, dreams and fantasies; (2) nongenital peripheral mechanisms such as salivation, sweating, cutaneous vasodilation and nipple erection; and (3) genital mechanisms such as clitoral, labial and vaginal engorgement. Orgasm involves the altered state of consciousness associated with sensory input primarily genital. Orgasm consists of multiple sensory afferent information from trigger points such as clitoris, labia, vagina, periurethral glans, etc, which pass centrally to supraspinal structures probably involving the thalamic septum. Following suf®cient sensory stimulation, central neurotransmitter discharge during orgasm results in repeated 1 sec motor contractions of the pelvic oor (3 ± 8aorgasm) followed in 2 ± 4 sec by repeated uterine and vaginal smooth muscle contraction. Pleasurable sensory information is also carried to the cortical pleasure sites. Orgasm involves a central thalamic sensory depolarizing wave resulting in synchronous motor activity following suf®cient sexual stimulation and arousal. 3 A speci®c and thorough description of the sexual problems a woman experiences is achieved through nosology. Female sexual dysfunction consists of disorders of desire, arousal, orgasm and sexual pain. Speci®cally for this review, the focus will be upon the condition of female sexual arousal disorder. Sexual arousal disorder is de®ned as the persistent or recurring inability to attain, or maintain adequate sexual excitement causing personal distress. It may be experienced as a lack of subjective excitement or a lack of genital (lubricationaswelling) or other somatic responses. 2 Disorders of female sexual arousal include, but are not limited to, lack of or diminished vaginal lubrication, decreased clitoral and labial sensation, decreased clitoral and labial engorgement or lack of vaginal smooth muscle relaxation. These conditions may occur secondary to psychological factors. However, there is often a medical or physiologic basis such as diminished vaginalaclitoral blood¯ow, altered hormonal milieu, prior pelvic trauma, pelvic surgery such as hysterectomy, vaginal injury from childbirth, or use of medications such as selective serotonin re-uptake inhibitors.
Female sexual dysfunction is a multi-causal and multi-dimensional medical problem that adversely effects physical health and emotional well being. The focus of this paper is to update new insights into the epidemiology, physiology, pathophysiology, diagnosis and treatment of the speci®c disorder of female sexual arousal.
Epidemiology
Epidemiologic investigations of women with female sexual dysfunction from well-designed, randomsample, community-based populations are limited. Based on available information, female sexual dysfunction is common and estimated to occur in 22 ± 43% of women. 4 ± 7 There are limited data on age-related and para-aging risk factors, both critical to plan treatments and prevention efforts. Based on correlates of female sexual dysfunction, associated risk factors include age, education, history of sexual abuse or sexually transmitted disease, overall state of general happiness and physical health. Epidemiologic information from the large, well-designed National Health and Social Life Survey revealed that in 1622 US women between the ages of 18 and 59 y, trouble lubricating and sex not pleasurable was noted in 18.8% and 21.2%, respectively, of the subjects. Overall, 43% of female subjects had complaints of sexual dysfunction. Women over the age of 60 were not included in this study, and no adjustment or association was made for menopausal status or medical risk factors. 4, 5 Rosen et al, in a non-population based study of 329 women aged 18 ± 73 y from a wellness outpatient gynecology center, reported that lack of sexual pleasure and lack of lubrication was noted in 16.3% and 13.65%, respectively, of the subjects. Based on the 1997 US Department of Commerce Bureau of the Census, 26 million women are postmenopausal. According to Rosen, 66% of postmenopausal women have intercourse, 45% and 20% have two and 10 intercourse occasions per month, respectively. Thus, 17 million post-menopausal women are engaging in 600 million intercourse occasions per year in the USA. Also according to Rosen, 57% experience lack of lubrication; 13% in 37.5% and 44% in greater than 75% of intercourse occasions, respectively. Thus, 9.7 million women experience lack of lubrication in 229 million intercourse occasions per year. 7 Ongoing epidemiologic studies in women suggest that the same disease processes and risk factors that are associated with male erectile dysfunction including aging, hypertension, cigarette smoking, hypercholesterolemia, are also associated with female sexual dysfunction.
Anatomy and physiology
There are multiple anatomical structures which comprise the internal and external female genital tract such as the clitoris, labia minora and vestibular (corpus spongiosum) erectile tissue, peri-urethral glans, urethra, G-spot, Halban's fascia, anterior fornix erogenous zone, pubococcygeus muscle and cervix. There are also multiple non-genital peripheral anatomic structures involved in female sexual responses such as salivary and sweat glands, cutaneous blood vessels and nipples. 8 ± 12 In response to neurogenic stimulation, clitoral and vaginal smooth muscle tone relax allowing for increased blood¯ow, vaginal and clitoral engorgement and increases vasocongestion. Thus, the state of smooth muscle tone determines the changes in the hemodynamic and genital arousal. 13 Sexual stimulation results in physiologic arousal or sensory afferent activation of these structures ultimately leading to an orgasmic response. In particular, the clitoris consists of two corpora cavernosa lined by the tunica albuginea. The internal erectile tissue includes endothelial-lined lacunar spaces, trabecular smooth muscle and trabecular connective tissue (collagen and elastin). Efferent autonomic innervation occurs via the cavernosal nerve. In the basal state, corporal smooth muscle is under contractile tone. Following sexual stimulation, neurogenic-and endothelial-mediated release of nitric oxide (NO) plays an important role in clitoral cavernosal artery and helicine arteriolar smooth muscle relaxation leading to clitoral engorgement. With sexual stimulation, increased blood ow to the clitoral cavernosal arteries results in increased clitoral intracavernosal pressure and tumescence and protrusion of the glans. Studies show that the clitoris achieves tumescence, but not rigidity or effective corporal veno-occlusion during sexual arousal. Duplex ultrasounds of the clitoris reveal that during sexual simulation the clitoris increases in length and diameter and blood¯ow almost doubles. In the clitoris, NO has been identi®ed in human tissue and is hypothesized to be the primary mediator of clitoral and labial engorgement. Organ bath analysis of rabbit clitoral cavernosal smooth muscle strips demonstrates enhanced relaxation in response to sodium nitroprusside and L-arginine (both NO donors) which supports the above hypothesis. Recently, phosphodiesterase Type V (PDE V), the enzyme responsible for degradation of cGMP, has been isolated in human clitoral smooth muscle cell culture and is inhibited by sildena®l citrate. 14 ± 18 The labia minora or corpora spongiosa are paired structures, each 3 cm in length, that lie along the sides of the vaginal ori®ce. They are composed of vascular smooth muscle and are separated from the clitoris, urethra and vestibule of the vagina. The main arterial supply is via bulbar, inferior perineal and posterior labial branches of the internal pudendal artery. The somatic sensory innervation of the labia minora travels via the perineal and posterior labial branches of the pudendal nerve. Autonomic innervation consists of sympathetic and parasympathetic ®bers that travel with the vessels to reach the vestibular bulb. In the labia minora, blood¯ow increases, particularly to the vestibular bulbs and causes a two-to three-fold increase in diameter and eversion of the labia with exposure of its inner surface. 13 The vagina consists of a tube of autonomicallyinnervated smooth muscle (longitudinal outer, inner circular layer) lined by strati®ed squamous epithelium and a sub-dermal layer rich in capillaries. Three sets of skeletal muscles surround the vagina including the ischiocavernosum, bulbocavernous, transverse perinei and levator ani and pubococcygeus muscles. In the basal state, the vaginal smooth muscle is under contractile tone and the epithelium reabsorbs sodium from the submucosal capillary plasma transudate. Following sexual stimulation, neurotransmitters modulate vaginal and vaginal arteriolar smooth muscle relaxation. Dramatic increases in capillary in¯ow in the submucosa overwhelms Na -reabsorption leading to 3 ± 5 ml vaginal transudate enhancing lubrication essential for pleasurable coitus. Engorgement of the vaginal wall raises intra-capillary pressure and increases transudation of plasma through the vaginal epithelium. This vaginal lubricative plasma¯ows through the epithelium onto the surface of the vagina, initially forming sweat-like droplets that coalesce to form a lubricative ®lm that covers the vaginal wall. Additional moistening during intercourse comes from secretions of the paired greater vestibular or Bartholin's glands, although some believe that these glands have a more primal function of emitting an odiferous¯uid to attract the male. The vaginal canal is also lubricated by secretions from cervicalauterine glands. In addition to lubricating, the vagina lengthens and dilates during sexual arousal as a result of relaxation of the vaginal wall smooth muscle. In human and animal models, sexual stimulation results in increased vaginal blood¯ow and decreases vaginal luminal pressure. 19 ± 26 Park et al reported that pelvic nerve stimulation in female New Zealand White rabbits, caused a 236% increase in vaginal blood¯ow, a 198% increase in vaginal wall pressure and a 114% increase in vaginal length. 13 Vaginal luminal pressure, as measured by balloon catheter in the vaginal canal, decreased with pelvic nerve stimulation. Injection of papaverine hydrochloride and phentolamine mesylate into the vaginal spongy muscularis layer increased vaginal wall pressure and vaginal blood¯ow, whereas injection of saline did not change vaginal wall pressure or blood¯ow. Histologic and arteriographic examination showed that the ilio-hypogastric-pudendal arterial bed in these control animals were normal. Using a novel, noninvasive laser oximeter technique, changes in the hemodynamics of the vagina are assessed by monitoring changes in the fraction of blood oxyhemoglobin and deoxyhemoglobin. A rise in the fraction of oxyhemoglobin and decrease in the fraction of deoxyhemoglobin is observed in response to pelvic nerve stimulation.
Immunohistochemical studies in human vaginal tissues have shown presence of nerve ®bers containing neuropeptide Y (NPY), vasoactive intestinal peptide (VIP), nitric oxide synthetase (NOS), calcitonin gene-related peptide (CGRP) and substance P. Preliminary studies suggest that VIP and NO are involved in modulating vaginal relaxation and secretory processes. Human and rabbit vaginal smooth muscle cells treated with the nitric oxide donor, sodium nitroprusside, in the presence of sildena®l, have enhanced intracellular cGMP synthesis and accumulation. PGE1 and forskolin also produced a marked increase in intracellular cGMP. In organ bath studies, sildena®l causes dose-dependent relaxation of female rabbit vaginal smooth muscle strips further suggesting a role for NO as a mediator of vaginal wall smooth muscle relaxation. However, the exact identity of the relaxatory nonadrenergicanon-cholinergic (NANC) neurotransmitter remains unclear. VIP is a NANC neurotransmitter that, like NO, may play a role in enhancing vaginal blood¯ow, lubrication and secretions. The vagina is heavily innervated with VIP-immunoreactive nerve ®bers in close relation to the epithelium and blood vessels. In organ bath studies, VIP also causes dose dependant relaxation of rabbit vaginal smooth muscle tissue, suggesting a similar role for endogenous VIP as a NANC neurotransmitter in vaginal tissues. 19 ± 26 Preliminary organ chamber experiments using rabbit vaginal tissue suggest that adrenergic mechanisms modulate smooth muscle tone. Exogenous norepinephrine (an alpha-1 and alpha-2 agonist) causes dose-dependent contraction of vaginal smooth muscle and alpha-1 (prazosin and tamsulosin) and alpha-2 (delaquamine) selective antagonists inhibit the contraction. These observations suggest that adrenergic nerves mediate the contractile response. Furthermore, there appears to be a difference in the quality of the contractile responses in upper and lower vaginal segments, which is consistent with their different innervation and embryologic origin. 8 ± 26 There are large gaps in our understanding of central nervous system control of female sexual function. The sexual arousal responses of the 
Diagnosis
There is no consensus as to the routine diagnostic algorithm of the female with sexual dysfunction. Basic features of diagnosis include history (sexual, psychosocial and medical), physical examination (external genitalia, internal genitalia), psychologic interview (psychologic issues, partner relationship) and laboratory testing (estrogen, testosterone, glucose, CBC, creatinine, LFT's, cholesterol, UaA, Pap smear, vaginal cultures as considered appropriate). Patient (and partner) education (anatomy, physiology, epidemiology, risk factors, etc) as well as reversing modi®able causes such as medical conditions, medication-related sexual dysfunction and lifestyle changes should be performed prior to the initiation of treatment. All patients should be evaluated for emotional andaor relational issues that may be contributing to the sexual arousal problem. This includes the context in which the patient experiences her sexuality, her self-esteem and body image, and her ability to communicate her sexual needs with her partner. This is an integral component of the female sexual function evaluation. Emotional anda or relational issues should be addressed prior to treatment, and certainly prior to determining treatment ef®cacy. If ongoing therapy is desired or required, it should also be provided.
To assess subjective sexual function, in particular sexual arousal, several instruments are available. The Brief Index of Sexual Function Inventory (BISF-W), for example, is a validated 21 item self-reported inventory of sexual interest, activity, satisfaction and preference and discriminates between depressed, sexually dysfunctional, and healthy patients. Subjective sexual response data re¯ect the personal experience of the patient, an important variable to evaluate because the ultimate goal is to enhance the personal sexual experience of the woman. Intervention is not considered successful unless the woman is able to subjectively experience sexual arousal, pleasure and satisfaction. Thus, it is important to determine if physiological changes or improvement in blood¯ow translate into an improved sexual experience. For instance, a documented increase in blood¯ow is irrelevant unless the patient actually experienced increased arousal, sensation, and satisfaction re¯ected by the physiological change.
Specialized vascular tests for sexual arousal, such as genital blood¯ow testing of vaginal vasocongestion, has literature-based measures of validity and speci®city and may be utilized in selected cases. The most commonly used procedure is vaginal photoplethysmography which utilizes a tamponsized light sourceadetector to record vaginal blood volume (DC ampli®er) and vaginal pulse amplitude (AC ampli®er) during sexual stimulation. Alternative diagnostic procedures of genital blood¯ow include duplex Doppler ultrasonography (clitoral, labial, urethral, and vaginal peak systolic velocities and end diastolic velocities), laser Doppler and laser oximetry. Other procedures such as vaginal lubrication as re¯ected by pH and vaginal pressure ± volume changes are being evaluated. Normative data are limited, as most testing for sexual arousal follows sexual stimulation. It is important to note that objective vascular tests have repeatedly observed a lack of subjective awareness of the vaginal vasocongestive arousal. 24,27 ± 29 Specialized neurologic tests for sexual arousal may include somatosensory evoked potential and electromyography. Temperature and vibration testing of the clitoris and vagina have been utilized for assessment of genital sensory integrity and normative data are available. Such testing can be achieved as an out-patient and sexual arousal disorders associated with such conditions as multiple sclerosis and vaginal birth injury can be investigated with this technique.
Treatment
Concerning treatment of sexual arousal, there are limited safety and ef®cacy outcome investigations of the various treatment modalities. 
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The ideal approach to female sexual dysfunction is a collaborative effort between therapists and physicians and should include evaluation of the partner or spouse in the treatment process. There is a multifaceted nature of female sexual dysfunction. The context in which a woman experiences her sexuality is equally if not more important that the physiologic outcome she experiences, and these issues need to be determined before beginning medical therapy or attempting to determine treatment ef®cacy. Despite the presence of organic disease, there are often psychosocial, emotional andaor relational factors that contribute to female sexual dysfunction. For this reason, a comprehensive approach, addressing both psychological as well as physiologic factors is instrumental to the evaluation of female patients with sexual complaints. Psychologic therapy has demonstrated ef®cacy in disorders of sexual desire, primary orgasm and vaginismus sexual pain, but not in sexual arousal disorder. 30 ± 35 Estrogen andaor androgen replacement hormonal therapy may be useful in sexual desire, arousal, orgasmic and dyspareunia sexual pain disorders. Estrogen therapy is indicated in menopausal women (either spontaneous or surgical). Aside from relieving hot¯ushes, preventing osteoporosis, and lowering the risk of heart disease, estrogen replacement therapy results in improved clitoral sensitivity, increases libido, and decreased pain and burning during intercourse. Local or topical estrogen application relieves symptoms of vaginal dryness, burning, and urinary frequency and urgency. In menopausal or oophorectomized women, complaints of vaginal irritation, pain, or dryness are relieved with topical estrogen cream. A vaginal estradiol ring (Estring) is currently available, which delivers low-dose estrogen locally, and which may bene®t breast cancer patients and other women who are unable to take oral or transdermal estrogen. 36, 37 Testosterone treatment is used in combination with estrogen (Estrotest) in menopausal women, for symptoms of dyspareunia, or lack of vaginal lubrication, as well as for its vasoprotective effects. There are con¯icting reports regarding the bene®t of testosterone for treatment of pre-menopausal women. There are reports of testosterone replacement using DHEA (50 mgaday). Topical vaginal testosterone is used for treatment of vaginal lichen planus. The suggested dose of methyltestosterone for pre and post menopausal women range from 0.25 to 1.25 mgaday. The dose should be adjusted according to symptoms, free testosterone levels, and cholesterol, triglyceride HDL levels, and LFT's. Topical testosterone (methyltestosterone or testosterone proprionate) preparations can be made in 1 ± 2% formulations and should be applied up to three times per week. The potential side effects include weight gain, clitoral enlargement, increased facial hair, and hypercholesterolemia. Increased clitoral sensitivity, decreased vaginal dryness, and increased libido, have been reported with the use of a 2% testosterone cream. Side effects are similar to the oral preparation. 36 ± 38 Other treatment options with scant ef®cacy and safety evaluations for sexual arousal include vaginal lubricants, vaginal dilators, pelvic¯oor rehabilitation such as biofeedback electromyography and Kegel exercises.
Oral vasodilators, such as sildena®l, L-arginine, yohimbine, apomorphine and phentolamine, are being tested in Phase II clinical safety and ef®cacy trials. Concerning phentolamine, a pilot study in menopausal women with sexual dysfunction demonstrated enhanced vaginal blood¯ow and subjective arousal. Concerning sildena®l, a pilot study in women with spinal cord injury has demonstrated clinical ef®cacy over placebo. Topical prostaglandin E1 and vasoactive intestinal polypeptide are currently under investigation for use in women with sexual arousal disorder. 24 
Conclusion
Basic science and clinical research in FSD is needed to overcome the gender gap, achieve a more balanced therapeutic perspective between psychologic and physiologic factors and offer female patients enhanced opportunity for relief of a persistent or recurrent sexual condition which causes personal distress.
